Targeted therapy is the dominating segment. Its leadership is driven by the identification of actionable mutations such as KRAS, BRCA, and NTRK, allowing for mutation-specific personalized regimens that improve survival rates with lower toxicity compared to traditional chemotherapy.
AI is being utilized to accelerate the identification of novel molecular targets and enhance clinical decision-making. Companies like Pfizer are partnering with AI biotech startups to exploit data-derived insights, while algorithms are increasingly used for predictive modeling of treatment outcomes and early diagnosis.
AI is being utilized to accelerate the identification of novel molecular targets and enhance clinical decision-making. Companies like Pfizer are partnering with AI biotech startups to exploit data-derived insights, while algorithms are increasingly used for predictive modeling of treatment outcomes and early diagnosis.
The Asia-Pacific region is projected to be the fastest-growing market. This growth is fueled by an increasing incidence of pancreatic cancer, a large patient population, rising healthcare investments in China, India, and Japan, and the rapid integration of AI-based diagnostic platforms.
The market faces significant obstacles, including high costs associated with precision diagnostics and targeted therapies, particularly in emerging markets. Additionally, the small number of patients available for clinical trials slows down therapy validation, and there is a critical need for multidisciplinary expertise and advanced clinical infrastructure.
Regulatory bodies, such as the FDA, are providing "breakthrough therapy" designations and fast-track approval pathways. These accelerants shorten the time it takes for innovative drug therapies to reach patients, thereby encouraging pharmaceutical firms to increase their investments in the sector.
Recent highlights include Bristol-Myers Squibb receiving FDA breakthrough therapy designation in February 2025, Merck & Co.’s 2024 partnership with Guardant Health for liquid biopsy technology, and Novartis AG’s alliance with Illumina to co-develop NGS-based companion diagnostics.
While single-agent immunotherapy has had limited success, combination strategies—pairing immune checkpoint inhibitors with chemotherapy or targeted therapies—are showing improved tumor responses and prolonged survival. This has made immunotherapy a high-investment sector for next-generation treatment strategies.
Key market players include Roche Holding AG, Pfizer Inc., Novartis AG, Bristol-Myers Squibb, Merck & Co., Inc., AstraZeneca PLC, Amgen Inc., Illumina Inc., Foundation Medicine, and Guardant Health.
